Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06605105Enrolling by invitationPhase 3
Long-term extension trial of CYB003 for depression
This long-term study is for people who already completed an earlier trial of the experimental drug CYB003 for major depression and who stayed on their regular antidepressant. It looks at the safety and effects of taking CYB003 again over many months.
Phoenix, ArizonaAges 18–85 - NCT06617325RecruitingPhase 3
New drug for moderate to severe lupus
This study tests a new medicine called Dapirolizumab Pegol (given as an infusion) for people with moderate to severe lupus (SLE) that is not well controlled despite standard treatments. It aims to see if the drug can reduce lupus activity and prevent flares.
Avondale, ArizonaAges 16 years+ - NCT06607458RecruitingPhase 2
Liver-focused chemo for metastatic colorectal cancer
This trial tests giving high-dose melphalan directly into the liver's blood supply, followed by standard cancer therapy, for people whose colorectal cancer has spread mainly to the liver. The goal is to see if this approach is safer and works better than standard treatment alone.
Duarte, CaliforniaAges 18 years+ - NCT06613698RecruitingPhase 2
Testing an investigational drug for alcohol-related liver disease
This trial tests whether a new drug, GSK4532990, is safe and effective compared to a placebo in adults aged 18 to 70 with liver disease caused by alcohol use. The study aims to see if the drug can help treat advanced chronic liver disease.
Chandler, ArizonaAges 18–70 - NCT06609239Enrolling by invitationPhase 2
Long-term safety study of Lunsekimig for asthma
This trial tests the long-term safety and effectiveness of Lunsekimig, an investigational drug, for adults with asthma. It is for people who have already completed a previous Lunsekimig study and are on stable asthma medications.
Chandler, ArizonaAges 18 years+ - NCT06602479RecruitingPhase 2
Study of MEDI0618 for episodic migraine
This trial tests a new medicine, MEDI0618, against a placebo for people with episodic migraine. The goal is to see if MEDI0618 is safe and effective at reducing migraine days.
Birmingham, AlabamaAges 18–70 - NCT06612645RecruitingPhase 1
CAR T cell therapy for children with solid tumors that returned
This trial tests a new type of immune therapy called CAR T cells designed to find and attack a protein called B7-H3 on solid tumor cells. It's for children and young adults whose cancer came back or didn't respond to standard treatment.
Bangkok, PathumwanAges 1–25 - NCT06612710RecruitingPhase 1
A study of NouvSoma001 for recent stroke recovery
This trial tests a new treatment called NouvSoma001 for people who have had an ischemic stroke within the last week. It aims to see if the treatment is safe and helps improve muscle strength and overall recovery.
Wuhan, HubeiAges 18–75 - NCT06600698RecruitingPhase 1/Phase 2
Herbal supplement for rising PSA in prostate cancer
This study tests an herbal supplement called AGN-INM176 in men with prostate cancer whose PSA is rising but whose cancer has not spread. It aims to see if the supplement can safely slow PSA rise without the need for hormone therapy or other treatments.
Hershey, PennsylvaniaAges 40 years+ - NCT06617182RecruitingPhase 2
Thalidomide and glutamine for radiation bowel injury
This trial tests whether combining thalidomide and glutamine helps people with bleeding caused by past radiation treatment to the abdomen or pelvis. The medication may reduce inflammation and help healing.
Xi'an, ShaanxiAges 18–80 - NCT06610266RecruitingPhase 4
Weifuchun tablet for stomach precancer reversal
This study tests if Weifuchun tablets can reverse precancerous changes called gastric intestinal metaplasia. If you have this condition and no H. pylori infection, you may qualify.
AnkangAges 18–75 - NCT06610760RecruitingPhase 4
Ursodeoxycholic acid for stomach precancer reversal
This trial tests if ursodeoxycholic acid can reverse intestinal metaplasia (a precancerous stomach condition) in patients who have no H. pylori infection. The goal is to see if this medication can help lower the risk of stomach cancer.
Pingdingshan, HenanAges 18–75 - NCT06609889RecruitingPhase 1/Phase 2
Testing a new drug for Lafora disease in young people
This trial tests an experimental drug called ION283, given by a lumbar puncture (spinal tap), to see if it is safe and can help with Lafora disease symptoms. It is for patients aged 10 to 18 with a confirmed genetic diagnosis.
Dallas, TexasAges 10–18 - NCT06588478RecruitingPhase 2
Study of pirtobrutinib for CLL or SLL
This trial tests a new drug called pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is for those whose cancer has come back or not responded to treatment, including a prior BTK inhibitor, and also for those who have never been treated but have a specific genetic change (17p deletion).
Chandler, ArizonaAges 18 years+ - NCT06597019RecruitingPhase 3
Study of inclisiran for children with high cholesterol
This trial tests a medicine called inclisiran to lower high cholesterol in children ages 6 to 12 with a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It may help children who still have high cholesterol despite taking other treatments.
San Francisco, CaliforniaAges 6–11 - NCT06596915RecruitingPhase 1
BA1302 for advanced solid tumors
This trial tests a new drug, BA1302, for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if BA1302 is safe and effective.
BeijingAges 18 years+ - NCT06599918RecruitingPhase 2
Nicotinamide for liver scarring in fatty liver disease
This study tests whether nicotinamide (a form of vitamin B3) can help reduce liver scarring in people with nonalcoholic fatty liver disease. You may qualify if you have moderate to severe liver scarring and are between 18 and 85 years old.
BarcelonaAges 18–85 - NCT06593197Enrolling by invitationPhase 4
Apremilast plus light therapy for vitiligo
This study tests whether adding a pill called apremilast to narrowband UVB light therapy works better than light therapy alone for vitiligo. It may help repigment the skin more effectively.
Karachi, SindhAges 18–70 - NCT06239311RecruitingPhase 3
Methotrexate vs placebo for adults with eczema
This trial tests if methotrexate, a medication that calms the immune system, can help adults with moderate-to-severe eczema that hasn't improved with creams or other treatments. You'll either receive methotrexate or a placebo to see which works better.
Prague, Praha 1Ages 18 years+ - NCT06443606RecruitingPhase 3
Bezafibrate for primary biliary cholangitis with incomplete UDCA response
This trial tests if adding bezafibrate (200 mg or 400 mg) to standard UDCA treatment can improve liver function in people with primary biliary cholangitis whose UDCA alone isn't working well enough.
ParisAges 18–80 - NCT06577519RecruitingPhase 3
Study of vicagrel for heart attack patients getting stents
This trial tests a new medicine called vicagrel for people who have had a heart attack or unstable angina and are getting a stent. The goal is to see if it works better than standard treatments to prevent future heart problems.
Shenyang, LiaoningAges 18–80 - NCT06567743RecruitingPhase 2
Study of a new virus therapy for high-risk bladder cancer
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
Gilbert, ArizonaAges 18 years+ - NCT06578507RecruitingPhase 2
Twice-daily hydroxyurea liquid for children with sickle cell disease
This trial tests a new twice-daily liquid form of hydroxyurea (a common SCD medicine) in children ages 9 months to 11 years with sickle cell disease. It will check how the medicine works in the body, if it is safe, and if it helps reduce pain crises and other complications.
CréteilAges 9 months–11 years - NCT06572384RecruitingPhase 3
Belimumab for lung scarring in autoimmune disease
This study tests whether a drug called belimumab can help people with lung scarring caused by certain autoimmune diseases (like rheumatoid arthritis or lupus). If you have active lung disease despite standard therapy, this trial may be an option.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.